Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-TRANSITION: Vunakizumab after switching from other biologics in adult moderate-to-severe plaque psoriasis
CTR20250905Phase 4Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of vunakizumab in plaque psoriasis, psoriatic arthritis (PsA), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2025; status: active.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20250905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250905.